Merck KGaA Appoints New CEO
Stefan Oschmann will replace new Karl-Ludwig Kley as chairman of the executive board and CEO of Merck KGaA.
On Oct. 13, 2015, Merck announced that Karl-Ludwig Kley will retire after serving nine years as chairman of the executive board and CEO of Merck KGaA. His replacement will be Stefan Oschmann, who has been a member of the executive board of Merck KGaA since 2011.
Johannes Baillou, chairman of the board of partners at E. Merck KG said in a press release that Oschmann's "strategic foresight and strong leadership have turned Merck KGaA, Darmstadt, Germany, into a respected player in the pharma industry again" and said that he hopes that Oschmann's new assignment will help the company navigate the "fundamental scientific and digital changes" that have been occurring in the industry.
Prior to his assignment as CEO of Merck KGaA, Stefan Oschmann worked for more than 20 years for the pharmaceutical company MSD Merck Sharp & Dohme, which is known in the United States as Merck & Co. He is currently president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and vice-president of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Source: Merck KGaA
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
